Industry voice questions ambition of UK's Innovative Medicines Fund

27 June 2022

National Health Service England and Improvement (NHSE/I) has announced the launch of the Innovative Medicines Fund (IMF), aimed at providing earlier access to certain promising new drugs while additional evidence is generated about their use.

This milestone has been welcomed by Paul Catchpole, director of value and access policy at the Association of the British Pharmaceutical Industry (ABPI), a trade group that represents the interests of pharma in the UK.

"An ideal place to deliver commercial approaches which support earlier patient access"It has been said that the IMF addresses a previous inequity where such access was only possible for oncology patients through the Cancer Drugs Fund (CDF). In the 10 years since that scheme was created, tens of thousands of oncology patients have benefited.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK